{"analyses":[{"ciLowerLimit":"0.593","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.979","estimateComment":"Stratified Cox Proportional Model","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0334","paramType":"Hazard Ratio (HR)","paramValue":"0.76","statisticalComment":"Stratified Log-Rank Test","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.52","upperLimit":"6.97","value":"5.8"},{"groupId":"OG001","lowerLimit":"4.17","upperLimit":"5.59","value":"4.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"266"},{"groupId":"OG001","value":"270"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"PFS is measured from the time of randomization until first documented disease progression or death from any cause, whichever is first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Margetuximab 15 mg/kg administered every 21 days with physician's choice of 1 of 4 backbone chemotherapy regimens.","id":"OG000","title":"Margetuximab Plus Chemotherapy"},{"description":"Trastuzumab administered every 21 days with physician's choice of 1 of 4 backbone chemotherapy regimens.","id":"OG001","title":"Trastuzumab Plus Chemotherapy"},{"description":"Margetuximab with or without chemotherap...","id":"OG002","title":"Margetuximab Infusion Substudy"}],"paramType":"MEDIAN","populationDescription":"The PFS outcome measure is calculated only for the randomized study efficacy population. The 88 participants in the sub-study were not part of the efficacy population","reportingStatus":"POSTED","timeFrame":"Tumor assessments are conducted every 6 weeks for the first 24 weeks and then every 24 weeks until progression of cancer, average 5 months.","title":"Progression-free Survival (PFS) as Determined by Independent Radiological Review.","type":"PRIMARY","unitOfMeasure":"months"}